bilaterals.org logo
bilaterals.org logo

medicines


FTA with Peru: India may have to lower import duty on drugs
India may have to lower the import duty on pharmaceuticals for Peru in the discussions on the proposed free trade agreement (FTA) with the South American country.
Israel set to make a strong push for goods FTA
The present Indian government has relaunched the talks with Israel. Israel wishes to conduct talks on regular basis to conclude the deal at the earliest. Indian patent system and pharmaceutical related issues have been the reasons why the deal couldn’t progress.
RCEP: India in a Catch-22
India’s position in the RCEP is the most protectionist among all the member nations. India has been resisting demands from Korea & Japan on intellectual property clauses, and other nations on opening up markets.
As India set to sign FTA with Peru, govt seeks industry views on export import duty rates
If the trade equation between India and Peru is in imbalance it would be causing more harm than benefit to India.
EU-Mercosur trade agreement: A bad deal for transparency, policy coherence and access to medicines
Negotiations are now nearing completion and there are increasing concerns among public health advocates, patient and consumer organisations, and other stakeholders, both in Europe and the Americas.
South Centre statement on EU-MERCOSUR trade negotiations
EU-MERCOSUR trade negotiations must not impose TRIPS Plus provisions on protection and enforcement of intellectual property rights.
EU-Mercosur FTA puts at risk access to medicines in Brazil, new impact assessment study finds
The adoption of the measures proposed by the EU could put the sustainability of access to health policies in Brazil at risk, as they could sharply increase public expenditures on medicines.
Time for costly medicine monopolies to go from TPP trade talks
The latest plan to get the controversial trade deal up and running involves freezing some of its controversial rules, including rules for biologic drugs, an expensive class of medicines often used to treat conditions such as cancer and rheumatoid arthritis.
New paper explains TPP’s impact on access to medicines in member countries
As the TPP-11 meet to attempt to revive the TPP without the US, the research findings show how damaging the original medicine proposals would be.
India to oppose anti-generics proposals at RCEP meet
India firm in opposing proposals that could hinder global access to affordable generic drugs
India will not cross red lines on generic drugs in RCEP, but stay vigilant, say officials
Healthcare watchers are calling on India to resist RCEP
Access to affordable stents and other medical devices – Indian Government should reject the bullying tactics of the US based medical device industry
Access to health products is non-negotiable; the Indian Government should reject the bullying tactics of the US based medical device industry.
RCEP negotiations should not restrict global access to affordable medicines and vaccines
RCEP negotiations should not restrict global access to affordable medicines and vaccines
5 hidden costs of the RCEP to people and planet
The RCEP has hidden costs for people’s lives
RCEP: Robbing communities to extract profit
RCEP will give multinational corporations unprecedented rights
Free trade talks with EFTA grouping hit IPR, services wall
Switzerland insists on intellectual property commitments beyond TRIPS.
Sanofi Aventis Ukraine seeks to file claim to international court to protect investment in Ukraine
Sanofi Aventis Ukraine LLC, part of Sanofi global pharmaceutical company, seeks to file a claim against Ukraine to the International Investment Arbitration.
Foreign patent owners can challenge domestic judgments under international investment arbitration
The first ever final award on patents in international investment arbitration by ICSID in the case of Eli Lilly v. Canada has effectively cleared the way for raising future disputes by foreign IPR owners against domestic institutions which can result in stronger and robust IP protection regime.
Canada introduces patent term extensions for pharmaceutical patents
The new regime has been implemented in order to meet Canada’s obligations under the Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union
TPP 11 Sydney meeting vindicates community concerns
TPP 11 negotiators have agreed to suspend controversial clauses on medicine monopolies and some governments want to renegotiate other clauses, vindicating public interest group concerns